Clinical trial · no report yet · Phase 3
NCT06561607
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- NCT06561607 ↗
- Active, not recruiting
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- TQB2102 for Injection; Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
- Arms
- TQB2102 for Injection · Experimental
- Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) · Active comparator
- Enrollment
- 542 (estimated)
- Primary outcomes
- Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Start
- Oct 11, 2024
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06561607 · updated Sep 10, 2026